MindMed
a primary mechanism new mechanism of action of action for low affinity for receptors and antagonist at alpha system beta nicotinic receptors well established mechanism of action alpha adrenergic agonist autonomic nervous efficacy for withdrawal supported by preclinical work mild moderate high variability in response reduction of autonomically mediated symptoms side effect profile appears to be mor bradycardia mild cardiac risk dosing adjusted for renal and kidney function necessary dose taper medication schedule bolus dosing minimal | MindMed
Company
Deck Type
Sector
Industry
Deck date
May 2022
Slide
25 of 40
Related slides by other companies
Enochian Biosciences
Results
August 2023
mechanism of action a | Enochian Biosciences
Valneva
IPO
April 2021
mechanism of action of based vaccines is understood anti protective response with disease vaccines | Valneva
Hydrafacial
Investor Day
September 2022
the multiple mechanisms of action for | Hydrafacial
Hydrafacial
Investor Day
September 2022
the multiple mechanisms of action for | Hydrafacial
Other recent decks by MindMed
See all presentations (10 decks)
Investor Presentation
January 2025
Investor Presentation
December 2024
Investor Presentation
November 2024
Results
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io